Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050

Core Insights - Transgene and NEC Corporation presented positive data on TG4050, an individualized neoantigen therapeutic vaccine, at ASCO 2025, demonstrating 100% disease-free survival after a minimum of 2-year follow-up in patients with HPV-negative locally advanced head and neck cancer [1][6][2] - The Phase I trial met all endpoints, including safety, feasibility, immune activation, and disease-free survival, confirming the clinical proof of principle for TG4050 [2][3] - TG4050 is based on Transgene's myvac® platform and utilizes NEC's AI capabilities for optimizing antigen selection, showcasing the potential of individualized cancer vaccine programs [3][9] Company Overview - Transgene is a biotechnology company focused on developing virus-based immunotherapies for cancer treatment, with TG4050 as its lead asset [8][11] - The company is advancing its myvac® platform, which allows for the creation of personalized immunotherapies tailored to individual patients [9][10] - NEC Corporation contributes its AI expertise to enhance the neoantigen prediction system, which is crucial for the development of TG4050 [15][16] Clinical Development - The ongoing Phase I/II clinical trial of TG4050 aims to confirm the encouraging results in a larger patient population, with approximately 80 patients expected to be enrolled [4][5] - The Phase II part of the trial is currently underway, focusing on both immunological and clinical outcomes [5][4] - The trial is designed to evaluate the treatment benefits of TG4050 in patients at risk of relapse after surgery and adjuvant therapy [14][13]